FDA Approves INGREZZA SPRINKLE — Neurocrine Biosciences, Inc.

# FDA Approves Neurocrine Biosciences' INGREZZA SPRINKLE for Tardive Dyskinesia Treatment Neurocrine Biosciences, Inc. has received FDA approval for INGREZZA SPRINKLE (valbenazine tosylate), an oral sprinkle formulation of its established tardive dyskinesia therapy, expanding the company's addressable market by offering a more flexible dosing option for patients who may have difficulty swallowing capsules. The new formulation is expected to strengthen Neurocrine's competitive position in the movement disorder space while